Akeso Inc. operates operatesa s a biotech company. The compnay develops treatments and therapies for various types of diseases. Akeso serves cutomers worldwide

Next Day Disclosure Return

Announcements and Notices - [Placing / Issue of Shares under a General Mandate]

Completion Of Placing Of New Shares Under General Mandate

Placing Of New Shares Under General Mandate

Announcements and Notices - [Other - Business Update]

Voluntary Announcement - Nmpa Approved The New Drug Application Of (Ebronucimab, Pcsk9)

Voluntary Announcement - Nmpa Approved The Snda Of (Cadonilimab, Pd-1/Ctla-4) 
In Combination With Chemotherapy
As A First-Line Treatment For Gastric Cancer

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Next Day Disclosure Return

Completion Of Placing Of New Shares Under General Mandate

Placing Of New Shares Under General Mandate

Voluntary Announcement - Nmpa Approved The New Drug Application Of (Ebronucimab, Pcsk9)

Voluntary Announcement - Nmpa Approved The Snda Of (Cadonilimab, Pd-1/Ctla-4) In Combination With Chemotherapy As A First-Line Treatment For Gastric Cancer